Pfizer’s rheumatoid arthritis treatment tasocitinib has met its two of its three primary endpoints in a phase III trial. Primary …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

